Biohaven Faces Another Pipeline Upset, But Focus Remains On Migraine Portfolio

ALS Data For Verdiperstat Expected In 2022

 
• By Mandy Jackson
  
A Businessperson Stopping Colorful Dominoes From Falling On Desk
Late-stage failures have stopped Biohaven from achieving success outside of its migraine pipeline • Source: Alamy
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D